Project Grant R56DE034052

Award Date 9/19/24
Completion Date 9/18/25
Dollars Obligated $550K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Kansas City, MO 64108, USA
Similar Awards
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1,178,476.00 in funding to Oraliva, Inc. for the development of an AI-linked cytomics-on-a-chip tool to enable early identification and management of oral lichenoid lesions in primary care settings. The key products and services to be delivered through this 2-year, direct-to-Phase II project include: 1) designing...
This National Cancer Institute Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" will develop and validate a multi-stage, multi-modal biomarker to predict the risk of progression from oral premalignant lesions (OPLs) to oral cavity squamous cell carcinoma (OSCC). The project, titled "PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool," will use a combination of cytology, histology, and epigenomics to create a risk...
This $294,632 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) aims to develop an intraoral camera system that can detect and monitor early-stage dental caries (tooth decay) using targeted fluorescent nanoparticle technology. The awarded project, led by Greenmark Biomedical Inc., will prepare a minimally viable product (MVP) of the intraoral camera system and conduct...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $619,347 Project Grant under the Oral Diseases and Disorders Research Program (CFDA 93.121) to Light Research Inc., a small business based in Tucson, Arizona. The grant funds the development and optimization of a compact multimodal intraoral camera that integrates polarized white light imaging, autofluorescence imaging, optical coherence tomography, and near-infrared transillumination imaging modalities. This advanced...
This $390,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under its Oral Diseases and Disorders Research program (CFDA 93.121), supports research to leverage single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key products and services to be delivered include: Optimizing a high-throughput, single-cell co-culture system to isolate individual tumor-killing T...
This Project Grant award of $274,100.00, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate how oral cancers impact the trafficking and signaling of the Protease-Activated Receptor 2 (PAR2) in trigeminal neurons, and to develop nanoparticle drug delivery systems targeting PAR2 to alleviate oral cancer pain. The research, conducted by New York University, aims to...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop and commercialize a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer (HNC). The goal is to synthesize and characterize a small peptide-targeted fluorescence probe that can specifically stain HNC tumors to assist surgeons in identifying tumors and defining...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $109,548 Project Grant under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121) to the Regents of the University of Michigan. The grant supports a research project focused on investigating the role of myeloid cells in the evolution of precancerous oral lesions to head and neck squamous cell carcinoma (HNSCC). The project aims to develop a preclinical mouse model to study the transition from...
This $434,170 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports the development and evaluation of a novel engineered bacterial in situ vaccination platform for oral cancer immunotherapy. The key products and services to be delivered under this award include: Development of potent and programmable non-pathogenic E. coli bacteria that can be biomaterial-encapsulated to...
This $162,216 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports the ADA Forsyth Institute's research to investigate microbe-microbe interactions within the oral microbiome. The study aims to employ a combination of expansion microscopy and multiplex FISH imaging to analyze microbial organization and quantify adhesion forces at the single-cell level. This approach...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), provides $550,296.00 to develop a multimodal imaging-based diagnostic system for assessing the risk of precancerous oral lesions. The key products and services to be delivered under this award include:

  1. Development of machine learning and deep learning models using Fourier transform infrared (FTIR) imaging techniques to stratify the risk of oral potentially malignant disorders (OPMDs).
  2. Integration of FTIR imaging with histological imaging to improve the diagnostic efficiency and accuracy for OPMD risk assessment.
  3. Application of spatial transcriptomics to profile gene expression and enhance the biological interpretability of the OPMD diagnostic platform.

The goal is to create a quantitative, objective, and accurate risk assessment system for individual OPMDs that can be integrated into the existing clinical diagnostic workflow, ultimately leading to improved patient outcomes and reducing the global burden of oral cancer. The award period runs from September 19, 2024, to September 18, 2025.

Generated 5/13/25, 1:59 AM